Health Canada has granted a Notice of Compliance (NOC) for Imfinzi® (durvalumab) for the treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine and ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

The supplemental Biologics License Application for the gastric/GEJ cancer indication is supported by data from the double-blind, placebo-controlled MATTERHORN trial.

The US Food and Drug Administration (FDA) has granted priority review to durvalumab for the treatment of patients with resectable, stage II-IVA gastric or gastroesophageal junction (GEJ) cancer.

AstraZeneca (($AZN)) has held its Q2 earnings call. Read on for the main highlights of the call. AstraZeneca’s recent earnings call showcased a ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of ...

Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic ...

AstraZeneca has received a positive recommendation from NICE for the use of Imfinzi (durvalumab) with Imjudo (tremelimumab) ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.

AstraZeneca (LSE:AZN) recently reported robust earnings results, with significant year-over-year increases in sales, revenue, ...